Last reviewed · How we verify
HPN-07
At a glance
| Generic name | HPN-07 |
|---|---|
| Also known as | disufenton sodium, Disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide |
| Sponsor | Otologic Pharmaceutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (PHASE2)
- Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC (PHASE1)
- Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE2)
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPN-07 CI brief — competitive landscape report
- HPN-07 updates RSS · CI watch RSS
- Otologic Pharmaceutics, Inc. portfolio CI